摘要
慢性腎臟病(chronic kidney disease, CKD) 與心血管疾病(cardiovascular disease, CVD) 密切相關,透析病人因CVD 導致死亡的風險約為一般人口的20 倍以上。醛固酮與鹽皮質激素受體(mineralocorticoid receptor, MR) 過度活化會促進體液滯留、發炎與纖維化,加重腎臟與心血管負擔,因此鹽皮質激素受體拮抗劑(mineralocorticoid receptor antagonists, MRAs) 被視為潛在治療選項。雖然MRAs 已在心衰竭及非透析CKD 病人中展現部分益處,但在透析病人的臨床試驗有限。近期的隨機對照試驗(如ALCHEMIST、ACHIEVE)顯示spironolactone 未能降低主要心血管事件或死亡率,且顯著增加高血鉀與男性乳房相關副作用。整體而言,目前缺乏針對透析族群的充分臨床證據,其療效與安全性仍待釐清。本文回顧MRAs 在透析病人心血管預防的最新證據,並探討未來研究方向。
ABSTRACT
Chronic kidney disease (CKD) is closely associated with cardiovascular disease (CVD), and patients on dialysis have an approximately 20-fold higher risk of CVD-related mortality compared with the general population. Overactivation of the aldosterone–mineralocorticoid receptor (MR) pathway promotes fluid retention, inflammation, and fibrosis, thereby exacerbating renal and cardiovascular burden. Consequently, mineralocorticoid receptor antagonists (MRAs) have been considered a potential therapeutic strategy.
While MRAs have demonstrated clinical benefits in heart failure and in non-dialysis CKD populations, evidence in dialysis patients remains limited. Recent randomized controlled trials (e.g., ALCHEMIST and ACHIEVE) showed that spironolactone did not reduce major ardiovascular events or mortality in hemodialysis patients, but was associated with an increased risk of hyperkalemia and gynecomastia-related adverse events.
Overall, robust clinical data on the efficacy and safety of MRAs in dialysis patients are still lacking. This review summarizes the latest evidence on MRAs for cardiovascular prevention in dialysis patients and highlights directions for future research.
Submitted for publication: 2025.10.07; Accepted for publication: 2026.01.19